Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1896 1
1965 1
1974 2
1975 1
1977 1
1978 2
1981 1
1983 1
1984 1
1985 1
1986 2
1991 1
1992 1
1999 1
2001 2
2003 1
2004 3
2005 1
2006 2
2007 1
2009 2
2010 1
2011 5
2012 7
2013 6
2014 9
2015 11
2016 13
2017 11
2018 14
2019 11
2020 5
2021 10
2022 4
2023 8
2024 10
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA. Nishio M, et al. Among authors: goldschmidt j jr. J Thorac Oncol. 2021 Apr;16(4):653-664. doi: 10.1016/j.jtho.2020.11.025. Epub 2020 Dec 14. J Thorac Oncol. 2021. PMID: 33333328 Free article. Clinical Trial.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Fehrenbacher L, et al. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10. Lancet. 2016. PMID: 26970723 Clinical Trial.
Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain.
Zimmermann S, Mathew A, Bondareva O, Elwakiel A, Waldmann K, Jiang S, Rana R, Singh K, Kohli S, Shahzad K, Biemann R, Roskoden T, Storsberg SD, Mawrin C, Krügel U, Bechmann I, Goldschmidt J, Sheikh BN, Isermann B. Zimmermann S, et al. Among authors: goldschmidt j. Kidney Int. 2024 Dec;106(6):1101-1116. doi: 10.1016/j.kint.2024.06.028. Epub 2024 Jul 30. Kidney Int. 2024. PMID: 39089576 Free article.
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Goldschmidt J, Hart L, Scott J, Boykin K, Bailey R, Heritage T, Lopez-Gonzalez L, Zhou ZY, Edwards ML, Monnette A, Ogbonnaya A, Deyoung K, Venkatasetty D, Shi P, Aton L, Huang H, Conkling PR, Gordan L. Goldschmidt J, et al. Adv Ther. 2023 Oct;40(10):4189-4215. doi: 10.1007/s12325-023-02601-2. Epub 2023 Jul 25. Adv Ther. 2023. PMID: 37490258 Free PMC article. Review.
Noncanonical microglial IL-1β maturation in chronic kidney disease.
Zimmermann S, Mathew A, Bondareva O, Elwakiel A, Jiang S, Rana R, Bechmann I, Goldschmidt J, Klöting N, Sheikh BN, Isermann B. Zimmermann S, et al. Among authors: goldschmidt j. Nephrol Dial Transplant. 2025 Apr 28;40(5):929-942. doi: 10.1093/ndt/gfae239. Nephrol Dial Transplant. 2025. PMID: 39496522
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, Felip E. Neal JW, et al. Among authors: goldschmidt j. JTO Clin Res Rep. 2024 Mar 20;5(10):100666. doi: 10.1016/j.jtocrr.2024.100666. eCollection 2024 Oct. JTO Clin Res Rep. 2024. PMID: 39318387 Free PMC article.
135 results